November 30, 2023 02:51 PM ESTUpdated 04:37 PM
FDA+

More com­pa­nies need to set di­ver­si­ty en­roll­ment goals in can­cer tri­als, FDA says

Zachary Brennan

Senior Editor

The FDA re­leased draft guid­ance back in April 2022 rec­om­mend­ing that bio­phar­ma spon­sors vol­un­tar­i­ly sub­mit plans to ex­plain how they plan to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times